Optimisation and Scale‐Up of the Heterologous Production of the Antifungal Protein PeAfpA From Penicillium expansum in Stirred‐Tank Bioreactors
Microbial Biotechnology · 2026-07 · 19 (7)
DOI: 10.1111/1751-7915.70414 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbial Biotechnology, online erschienen am 15.07.2026. Verfasst von Stefani de Ovalle und 6 weiteren Autor:innen. Beteiligte Einrichtung: Instituto de Agroquímica y Tecnología de Alimentos (IATA) Consejo Superior de Investigaciones Científicas (CSIC), Paterna, Valencia, Spain. Hauptthemen laut MEDLINE: Bioreactors, Fungal Proteins, Penicillium chrysogenum, Penicillium. Die Arbeit nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministerio de Ciencia, Innovación y Universidades, Ministerio de Ciencia e Innovación, Consejo Superior de Investigaciones Científicas.
Abstract (Originalsprache)
Antifungal proteins from fungal origin (AFPs) are small, secreted, cationic, cysteine‐rich proteins with potential as novel biofungicides. However, their application requires safe and cost‐effective production platforms. PeAfpA is a highly active AFP naturally produced in large quantities by the phytopathogenic fungus Penicillium expansum and biotechnologically produced by the Generally Recognized As Safe fungus Penicillium chrysogenum although at lower yields . Here, the production of PeAfpA using the P. chrysogenum strain PCMG11552 was optimised in 0.5 L and scaled up to 5 L in stirred‐tank bioreactors. A competitive enzyme‐linked immunosorbent assay (cELISA) was developed to evaluate the influence of process parameters on PeAfpA production, identifying medium pH and agitation rate as key factors, while dissolved oxygen proved critical during scale‐up. The PeAfpA yields obtained were tenfold higher than those achieved previously in flask cultures, demonstrating the feasibility of scaling AFP production from laboratory to pilot scale for diverse applications. Finally, the P. chrysogenum marker‐free PeAfpA‐producing strain obtained via recyclable CRISPR/Cas9 system guarantees regulatory compliance and biosafety, making it suitable for its use in any commercial environment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Instituto de Agroquímica y Tecnología de Alimentos (IATA) Consejo Superior de Investigaciones Científicas (CSIC), Paterna, Valencia, Spain.
ORCID-Profile: Josep V Mercader, Paloma Manzanares
Förderung
- Ministerio de Ciencia, Innovación y Universidades
- Ministerio de Ciencia e Innovación
- Consejo Superior de Investigaciones Científicas
Zitieren
APA
de Ovalle, S., Garrigues, S., Gimeno-Alcañiz, J. V., Mercader, J. V., Abad-Fuentes, A., Marcos, J. F., & Manzanares, P. (2026). Optimisation and Scale‐Up of the Heterologous Production of the Antifungal Protein PeAfpA From Penicillium expansum in Stirred‐Tank Bioreactors. Microbial Biotechnology, 19(7). https://doi.org/10.1111/1751-7915.70414
Vancouver
de Ovalle S, Garrigues S, Gimeno-Alcañiz JV, Mercader JV, Abad-Fuentes A, Marcos JF, et al. Optimisation and Scale‐Up of the Heterologous Production of the Antifungal Protein PeAfpA From Penicillium expansum in Stirred‐Tank Bioreactors. Microbial Biotechnology. 2026;19(7). doi:10.1111/1751-7915.70414
BibTeX
@article{deOvalle2026,
author = {de Ovalle, Stefani and Garrigues, Sandra and Gimeno-Alcañiz, Jose V and Mercader, Josep V and Abad-Fuentes, Antonio and Marcos, Jose F and Manzanares, Paloma},
title = {Optimisation and Scale‐Up of the Heterologous Production of the Antifungal Protein PeAfpA From Penicillium expansum in Stirred‐Tank Bioreactors},
journal = {Microbial Biotechnology},
year = {2026},
volume = {19},
number = {7},
doi = {10.1111/1751-7915.70414}
}
EUVIMED